progesterone congeners

Summary

Summary: Steroidal compounds related to PROGESTERONE, the major mammalian progestational hormone. Progesterone congeners include important progesterone precursors in the biosynthetic pathways, metabolites, derivatives, and synthetic steroids with progestational activities.

Top Publications

  1. ncbi Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    Jacques E Rossouw
    Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
    JAMA 288:321-33. 2002
  2. ncbi Different cardiovascular effects of progestins according to structure and activity
    A Nath
    Tietze fellow from the Population Council, New York, NY, USA
    Climacteric 12:96-101. 2009
  3. ncbi Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy
    Stefano Lello
    Endocrinological Gynecology, Pathophysiology of Menopause and Osteoporosis Unit, IRCCS Istituto Dermopatico dell Immacolata, Rome, Italy
    Drugs 70:541-59. 2010
  4. ncbi Drospirenone in combination with estrogens: for contraception and hormone replacement therapy
    W H K Oelkers
    Endokrinologikum, Berlin, Germany
    Climacteric 8:19-27. 2005
  5. ncbi Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate
    Tommaso Simoncini
    Molecular and Cellular Gynecological Endocrinology Laboratory MCGEL, Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
    Obstet Gynecol 108:969-78. 2006
  6. ncbi Nomegestrol acetate: steroid receptor transactivation profile in Chinese hamster ovary cells and ovulation inhibition in rat and monkey
    Harry A van Diepen
    Women s Health Department, Merck Research Laboratories, Oss, The Netherlands
    Contraception 84:199-204. 2011
  7. ncbi Nomegestrol acetate, a novel progestogen for oral contraception
    Alfred O Mueck
    Department of Endocrinology and Menopause, University Women s Hospital, Calwer Strasse 7, DE 72076, Tubingen, Germany
    Steroids 76:531-9. 2011
  8. ncbi Nomegestrol acetate and vascular reactivity: nonhuman primate experiments
    J M Paris
    Laboratoire Theramex, BP 59, 6 Avenue Prince Hereditaire Albert, 98007, Monaco
    Steroids 65:621-7. 2000
  9. ncbi Effect of nomegestrol acetate on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T-47D breast cancer cell lines
    Gerard Samuel Chetrite
    Hormones and Cancer Research Unit, Institut de Puericulture, 26 Boulevard Brune, 75014 Paris, France
    Anticancer Res 23:4651-5. 2003
  10. ncbi The pharmacology of nomegestrol acetate
    Xiangyan Ruan
    Department of Gynecological Endocrinology, Beijing OB GYN Hospital, Capital Medical University, Beijing, China
    Maturitas 71:345-53. 2012

Detail Information

Publications258 found, 100 shown here

  1. ncbi Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    Jacques E Rossouw
    Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
    JAMA 288:321-33. 2002
    ..Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain...
  2. ncbi Different cardiovascular effects of progestins according to structure and activity
    A Nath
    Tietze fellow from the Population Council, New York, NY, USA
    Climacteric 12:96-101. 2009
    ..Although it is likely that the new progestins may be neutral on the coronary disease risk, when administered to the younger postmenopausal woman, this has not as yet been documented by large, randomized, controlled trials...
  3. ncbi Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy
    Stefano Lello
    Endocrinological Gynecology, Pathophysiology of Menopause and Osteoporosis Unit, IRCCS Istituto Dermopatico dell Immacolata, Rome, Italy
    Drugs 70:541-59. 2010
    ....
  4. ncbi Drospirenone in combination with estrogens: for contraception and hormone replacement therapy
    W H K Oelkers
    Endokrinologikum, Berlin, Germany
    Climacteric 8:19-27. 2005
    ....
  5. ncbi Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate
    Tommaso Simoncini
    Molecular and Cellular Gynecological Endocrinology Laboratory MCGEL, Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
    Obstet Gynecol 108:969-78. 2006
    ..The aim of this study was to establish whether nomegestrol acetate induces signaling events in human endothelial cells that differ from those of other progestins, such as natural progesterone or medroxyprogesterone acetate...
  6. ncbi Nomegestrol acetate: steroid receptor transactivation profile in Chinese hamster ovary cells and ovulation inhibition in rat and monkey
    Harry A van Diepen
    Women s Health Department, Merck Research Laboratories, Oss, The Netherlands
    Contraception 84:199-204. 2011
    ..Activity of nomegestrol acetate (NOMAC), levonorgestrel (LNG), drospirenone (DRSP), dienogest (DNG) and progesterone on human steroid receptor transactivation was investigated. Ovulation inhibition by NOMAC, LNG and progesterone was tested...
  7. ncbi Nomegestrol acetate, a novel progestogen for oral contraception
    Alfred O Mueck
    Department of Endocrinology and Menopause, University Women s Hospital, Calwer Strasse 7, DE 72076, Tubingen, Germany
    Steroids 76:531-9. 2011
    ..These clinical findings are promising; however, full publication of results from the pivotal phase III trials of NOMAC/E2 is pending...
  8. ncbi Nomegestrol acetate and vascular reactivity: nonhuman primate experiments
    J M Paris
    Laboratoire Theramex, BP 59, 6 Avenue Prince Hereditaire Albert, 98007, Monaco
    Steroids 65:621-7. 2000
    ..In these two nonhuman primate cardiovascular models, NOMAC did not have the negating effects observed with MPA...
  9. ncbi Effect of nomegestrol acetate on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T-47D breast cancer cell lines
    Gerard Samuel Chetrite
    Hormones and Cancer Research Unit, Institut de Puericulture, 26 Boulevard Brune, 75014 Paris, France
    Anticancer Res 23:4651-5. 2003
    ....
  10. ncbi The pharmacology of nomegestrol acetate
    Xiangyan Ruan
    Department of Gynecological Endocrinology, Beijing OB GYN Hospital, Capital Medical University, Beijing, China
    Maturitas 71:345-53. 2012
    ....
  11. ncbi Certain progestins prevent the enhancing effect of 17beta-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells
    Murielle Zerr-Fouineau
    Département de Pharmacologie et Physico Chimie, Institut Gilbert Laustriat, Université Louis Pasteur Strasbourg I, Illkirch, France
    Arterioscler Thromb Vasc Biol 29:586-93. 2009
    ..This study examined whether progestins affect the stimulatory effect of estrogens on the endothelial formation of nitric oxide (NO), a potent antithrombotic factor...
  12. ncbi Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens
    E Lundstrom
    Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden
    Climacteric 4:42-8. 2001
    ..The aim of this study was to evaluate the impact of different hormone replacement therapy (HRT) regimens on mammographic breast density...
  13. ncbi [After the early termination of the Women's Health Initiative study. New American recommendations for postmenopausal hormone therapy]
    Martin Stjernquist
    Institutionen för obstetrik och gynekologi, Malmo, Lunds universitet, Kvinnokliniken, Universitetssjukhuset MAS, Malmo
    Lakartidningen 100:1790-7. 2003
    ..Establishing an individual risk profile is essential. The author of this article also emphasizes a restrictive attitude for patients with increased risk of thromboembolic disease...
  14. ncbi Trace elements and vitamin levels in menopausal women receiving hormone replacement therapy
    I Meram
    Department of Biochemistry, Medical Faculty, University of Gaziantep, Turkey
    Clin Exp Obstet Gynecol 30:32-4. 2003
    ..001). In conclusion we observed a beneficial effect of HRT on serum levels of trace elements, vitamin A, and vitamin E in addition to the well known other benefits...
  15. ncbi Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial
    Stephen R Rapp
    Department of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    JAMA 289:2663-72. 2003
    ..On July 8, 2002, the estrogen plus progestin therapy in the WHI trial was discontinued because of certain increased health risks for women...
  16. ncbi Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial
    Sally A Shumaker
    Department of Public Health Sciences, Wake Forest University Health Sciences, Winston Salem, NC 27104, USA
    JAMA 289:2651-62. 2003
    ..On July 8, 2002, the study drugs, estrogen plus progestin, in the Women's Health Initiative (WHI) trial were discontinued because of certain increased health risks in women receiving combined hormone therapy...
  17. ncbi A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone
    J H Meuwissen
    Diagnostisch Centrum, Eindhoven, The Netherlands
    Gynecol Endocrinol 15:349-58. 2001
    ..It was concluded that the E2 + TMG combination was either equivalent or superior to the E2V + NG combination in the treatment of hot flushes and other climacteric symptoms, and that its bleeding profile was favorable...
  18. ncbi The effect of medroxyprogesterone acetate and norethisterone on the estradiol stimulated proliferation in MCF-7 cells: comparison of continuous combined versus sequential combined estradiol/progestin treatment
    C Lippert
    Centre for Endocrinology and Menopause, Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany
    Eur J Gynaecol Oncol 22:331-5. 2001
    ..These findings might be useful in the elucidation of potential mechanisms involved in the clinical situation...
  19. ncbi Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys
    Irma H Suparto
    Comparative Medicine Clinical Research Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Am J Obstet Gynecol 188:1132-40. 2003
    ....
  20. ncbi Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial
    Rowan T Chlebowski
    Harbor UCLA Research and Education Institute, Torrance 90502, USA
    JAMA 289:3243-53. 2003
    ..Outstanding issues not previously addressed include characteristics of breast cancers observed among women using hormones and whether diagnosis may be influenced by hormone effects on mammography...
  21. ncbi Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women
    Inci Davas
    Second Obstetrics and Gynecology Clinic, Sisli Etfal Training and Research Hospital, Istanbul, Turkey
    Fertil Steril 80:536-40. 2003
    ..To evaluate the effect of daily oral and transdermal hormone therapy alone or in combination with alendronate on bone mineral density in postmenopausal women...
  22. pmc Combination hormone replacement therapy and dementia
    Eric Wooltorton
    CMAJ 169:133. 2003
  23. ncbi Effects of trimonthly progestin administration on the endometrium in elderly postmenopausal women who receive hormone replacement therapy: a pilot study
    Anil B Pinto
    Department of Obstetrics and Gynecology, Washington University School of Medicine, USA
    Am J Obstet Gynecol 189:11-5. 2003
    ..The purpose of this study was to determine the effect of trimonthly progestin administration on the endometrium in elderly postmenopausal women who receive hormone replacement therapy...
  24. ncbi Quantification of ovarian stromal Doppler signals in postmenopausal women receiving hormone replacement therapy
    Hsien An Pan
    Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, Tainan, Taiwan
    Menopause 10:366-72. 2003
    ..To investigate the effect of continuous-combined hormone replacement therapy (HRT) on ovarian circulation, we used three-dimensional power Doppler ultrasound to assess ovarian stromal blood flow in postmenopausal women...
  25. ncbi The relation of oxidized LDL autoantibodies and long-term hormone replacement therapy to ultrasonographically assessed atherosclerotic plaque quantity and severity in postmenopausal women
    T A Koivu
    The Research Laboratory of Atherosclerosis Genetics, Department of Clinical Chemistry, Centre for Laboratory Medicine, University Hospital of Tampere, PO Box 2000, 33521 Tampere, Finland
    Atherosclerosis 157:471-9. 2001
    ....
  26. ncbi Comparison of Pueraria lobata with hormone replacement therapy in treating the adverse health consequences of menopause
    Jean Woo
    Department of Community and Family Medicine, The Chinese University of Hong Kong, Hong Kong
    Menopause 10:352-61. 2003
    ..The scientific basis for its action may be its action as a phytoestrogen...
  27. ncbi Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels
    Vito Chiantera
    Department of Gynecology and Obstetrics, Fatebenefratelli Hospital, Naples, Italy
    Menopause 10:286-91. 2003
    ..To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT) on serum homocysteine levels in postmenopausal women...
  28. ncbi Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens
    J A Simon
    Women's Health Research Center, Laurel, Maryland, USA
    Menopause 8:321-7. 2001
    ..The potential for long-term treatment compliance based on better bleeding control may optimize the opportunity to prevent osteoporosis as well as other associated health benefits...
  29. ncbi Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes
    M Perera
    Department of Obstetrics and Gynaecology, University of Glasgow, G3 8SJ, UK
    Hum Reprod 17:497-502. 2002
    ..Observational studies have suggested that estrogens may provide cardioprotection by regulating endothelial nitric oxide synthase...
  30. ncbi Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial
    Mark A Hlatky
    Stanford University School of Medicine, HRP Redwood Bldg, Room 150, Stanford, CA 94305 5405, USA
    JAMA 287:591-7. 2002
    ..Postmenopausal hormone therapy is commonly used by women for disease prevention, but its effects on quality of life have not been well documented...
  31. ncbi Effects of hormone replacement therapy on serum angiotensin-converting enzyme activity and plasma bradykinin in postmenopausal women according to angiotensin-converting enzyme-genotype
    Hiroyuki Sumino
    Second Department of Internal Medicine, Gunma University School of Medicine, Showa machi, Maebashi, Japan
    Hypertens Res 26:53-8. 2003
    ..01, p < 0.01, and p < 0.01, respectively). These results suggest that the increased plasma bradykinin of PMW by HRT might not be induced solely by the reduction in serum ACE activity...
  32. ncbi Effects of tibolone and conventional hormone replacement therapies on arterial and hepatic cholesterol accumulation and on circulating endothelin-1, vascular cell adhesion molecule-1, and E-selectin in surgically menopausal monkeys
    Thomas C Register
    Comparative Medicine Clinical Research Center, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Menopause 9:411-21. 2002
    ....
  33. ncbi Discussing breast cancer and hormone replacement therapy with women
    Pelin Batur
    Department of General Internal Medicine, Gault Women s Health and Breast Pavilion, The Cleveland Clinic Foundation, Ohio 44195, USA
    Cleve Clin J Med 69:838, 840, 843-4 passim. 2002
    ..We discuss limitations of the study, questions that remain, and how to discuss the study with women at average risk and high risk for breast cancer...
  34. ncbi Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine
    Ingrid Os
    Department of Internal Medicine, Ulleval University Hospital, Oslo, Norway
    Cardiology 98:6-12. 2002
    ....
  35. ncbi [Tibolone]
    Christian Jamin
    Service de gynécologie obstétrique CHU Bichat, 46, rue Henri Huchard 75018 Paris
    Presse Med 31:1314-22. 2002
    ..Certain tissues (liver, endometrium) may metabolize the 3 beta ol derivative into the delta 4 isomer with progestagenic and androgenic activity. The metabolism of the product in other tissues such as the breast and brain is unknown...
  36. ncbi Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women
    Assen Goudev
    Department of Internal Medicine 2, Preventive Cardiology Clinic, Medical University Sofia, 1 G Sofiiski St, 1431 Sofia, Bulgaria
    Maturitas 43:49-53. 2002
    ..The effect of hormone replacement therapy (HRT) on these inflammatory markers is not uniform. In the presented study the effect of a low-dose HRT preparation, on sCAM, CRP and SAA in healthy postmenopausal women was evaluated...
  37. ncbi Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system
    T Simsek
    Department of Obstetrics and Gynecology, Akdeniz University School of Medicine, Antalya, Turkey
    Maturitas 42:243-6. 2002
    ..To assess the effect of different hormone replacement therapy regimens on myoma uteri in postmenopausal period...
  38. ncbi Failure of estrogen plus progestin therapy for prevention
    Suzanne W Fletcher
    JAMA 288:366-8. 2002
  39. ncbi Combination therapy of low-dose medroxyprogesterone acetate and oral estrogen does not affect endothelial function in the forearms of postmenopausal women
    Mitsuhiro Sanada
    Department of Obstetrics and Gynecology, Faculty of Medicine, Hiroshima University, Hiroshima, Japan
    Menopause 9:360-6. 2002
    ..We investigated whether low-dose medroxyprogesterone acetate (MPA) combined with oral estrogen had adverse effects on endothelial function compared with oral estrogen alone in postmenopausal women with mild hypercholesterolemia...
  40. ncbi National differences in lipid response to postmenopausal hormone replacement therapy
    Varpu Ranta
    Department of Obstetrics and Gynecology, Institute of Clinical Research, Helsinki University Central Hospital PB 140, 00029 Helsinki, Finland
    Maturitas 42:259-65. 2002
    ..To compare the response of serum lipids and lipoproteins to the transdermal hormone replacement therapy (HRT) in five European countries...
  41. ncbi Use of combination hormone replacement therapy in light of recent data from the Women's Health Initiative
    Andrew M Kaunitz
    University of Florida Health Science Center Jacksonville, USA
    Medscape Womens Health 7:8. 2002
  42. ncbi Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations
    Sven O Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, Denmark
    Am J Obstet Gynecol 186:969-77. 2002
    ..Our purpose was to assess the effect of hormone replacement therapy (HRT) on C-reactive protein blood concentrations with special reference to the progestin component...
  43. ncbi Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women
    K S Tsai
    Department of Laboratory Medicine, National Taiwan University Hospital and Medical College, Taipei, ROC
    Osteoporos Int 12:1020-5. 2001
    ..05). We conclude that in healthy, postmenopausal Taiwanese women, RLX 60 mg given daily has favorable results in BMD, bone turnover and serum lipids, although the dosage we used showed a potency less than that of conventional CCEP...
  44. ncbi The Women's Health Initiative estrogen plus progestin trial: the study and how it changes our practice
    Susan L Hendrix
    Wayne State University School of Medicine, Detroit, Mich, USA
    J Am Osteopath Assoc 103:S3-5. 2003
  45. ncbi The effects of hormonal therapy on aortic stiffness and left ventricular diastolic function
    Sevket Gorgulu
    Siyami Ersek Thoracic and Cardiovascular Surgery Center, Cardiology Department, Istanbul, Turkey
    Acta Cardiol 58:1-8. 2003
    ..The main objective of this study is to investigate the effects of oestrogen replacement therapy (ERT) and hormone replacement therapy (HRT) on aortic stiffness and on the left ventricular diastolic function, including tissue Doppler...
  46. ncbi Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response
    T Raudaskoski
    Department of Obstetrics and Gynaecology, Oulu University Hospital, Finland
    BJOG 109:136-44. 2002
    ....
  47. ncbi [WHI study on the attention of menopause in Spain: significance of its results]
    Santiago Palacios
    Instituto Palacios Antonio Acuña, 9 Local 28009 Madrid España
    Med Clin (Barc) 120:146-7. 2003
  48. ncbi Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal women
    Stefania Lamon-Fava
    Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111, USA
    Am J Cardiol 91:252-4. 2003
  49. ncbi Postmenopausal hormone therapy and change in mammographic density
    Gail A Greendale
    Division of Geriatric Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Natl Cancer Inst 95:30-7. 2003
    ..Mammographic density is an independent risk factor for breast cancer. Postmenopausal hormone use is associated with an increase in mammographic density, but the magnitude of the density increase is unknown...
  50. ncbi Oral 17beta-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women
    Bruno Pornel
    Brussels Menopause Center, Brussels, Belgium
    Menopause 9:171-8. 2002
    ..To investigate the effects of 1 mg 17beta-estradiol continuously combined with 2.5, 5, 10, or 20 mg dydrogesterone on the serum lipid profile of postmenopausal women...
  51. ncbi Autonomic and cardiovascular function in postmenopausal women: the effects of estrogen versus combination therapy
    Noha H Farag
    Department of Psychiatry, University of California, San Diego, UCSD Medical Center, 92103 0804, USA
    Am J Obstet Gynecol 186:954-61. 2002
    ..This study examined the effects of oral estrogen (ERT) alone versus oral estrogen/medroxyprogesterone acetate (HRT) therapy on cardiovascular function, as controlled by the autonomic nervous system...
  52. ncbi Six months of hormone replacement therapy does not influence muscle strength in postmenopausal women
    Eva L Ribom
    Department of Surgical Sciences, Section of Orthopaedics, University of Uppsala, Uppsala, Sweden
    Maturitas 42:225-31. 2002
    ..This has been attributed to increased muscle strength by HRT. This study was designed to evaluate the effect of 6 months of HRT on muscle strength in postmenopausal women...
  53. ncbi Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial
    Jane A Cauley
    Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA
    JAMA 290:1729-38. 2003
    ..In the Women's Health Initiative trial of estrogen-plus-progestin therapy, women assigned to active treatment had fewer fractures...
  54. ncbi Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women
    Filiz Cayan
    Department of Obstetrics and Gynecology, University of Mersin School of Medicine, Mersin, Turkey
    J Sex Med 5:132-8. 2008
    ..Sexual dysfunction is more prevalent in postmenopausal women...
  55. ncbi The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites
    Juana Enríquez
    Department of Reproductive Biology, Instituto Nacional de Ciencias Médicas y Nutrición S Zubirán INCMNSZ, Mexico City 14000, Mexico
    J Endocrinol 193:493-504. 2007
    ....
  56. ncbi Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study
    G Samsioe
    Department of Obstetrics and Gynecology, Lund University Hospital, Lund, Sweden
    Climacteric 9:368-79. 2006
    ..To establish whether transdermal continuous hormone replacement therapy (HRT) with estrogen/progestogen provides adequate long-term endometrial protection in postmenopausal women over a period of 96 weeks...
  57. ncbi alpha-Tocopherol and beta-carotene serum levels in post-menopausal women treated with transdermal estradiol and oral medroxyprogesterone acetate
    C Clemente
    Laboratory of Biochemistry, IRCCS S. De Bellis, Castellana G, Italy
    Horm Metab Res 28:558-61. 1996
    ..These preliminary findings suggest that HRT can preserve the content of alpha-tocopherol and beta-carotene in LDL particles and keep the LDL in a reduced antioxidant state...
  58. ncbi Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
    S Hulley
    University of California, San Francisco 94143, USA
    JAMA 280:605-13. 1998
    ..However, given the favorable pattern of CHD events after several years of therapy, it could be appropriate for women already receiving this treatment to continue...
  59. ncbi Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women
    Robert Lindsay
    Internal Medicine, Helen Hayes Hospital, Rte 9W, West Haverstraw, NY 10993, USA
    JAMA 287:2668-76. 2002
    ..This lower-dose therapy's protection against loss of bone mineral density (BMD) associated with menopause has not been thoroughly investigated...
  60. ncbi Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women
    See Kwok
    Barlow Medical Centre, 8 Barlow Moor Road, Manchester M20 6TR, UK
    Maturitas 53:439-46. 2006
    ....
  61. ncbi Progestins and estrogens and Alzheimer's disease
    Hideo Honjo
    Department of Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kawaramachi, Hirokoji, Kamigyo ku, Kyoto 602 8566, Japan
    J Steroid Biochem Mol Biol 93:305-8. 2005
    ..like E2. More investigations about progestins and estrogens and AD should be done...
  62. ncbi [Risk and benefits of hormone replacement therapy by postmenopausal women. WHI-Study]
    V Heinemann
    Medizinische Klinik II, Grosshadern, Klinikum der Ludwig Maximilians Universität München
    Internist (Berl) 44:896-8. 2003
  63. ncbi Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors
    F P Chen
    Department of Obstetrics and Gynecology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Republic of China
    Menopause 8:347-52. 2001
    ..However, it needs to be considered that there is an increased risk of venous thrombotic events in the first year of treatment...
  64. ncbi Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
    Giske Ursin
    Department of Preventive Medicine, Norris Comprehensive Cancer Center, Room 4407, USC Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
    J Clin Oncol 22:2842-8. 2004
    ..We determined whether increases in serum estrone as a function of treatment predict increases in mammographic percent density...
  65. ncbi Nondaily hormonal contraception: establishing a fit between product characteristics and patient preferences
    Jeffrey P Levine
    Departments of Family Medicine and Obstetrics, Gynecology and Reproductive Sciences, UMDNJ Robert Wood Johnson Medical School, 1 RWJ Place, CN19, New Brunswick, NJ 08903 0019, USA
    J Fam Pract 53:904-13. 2004
  66. ncbi Consortium for the Assessment of Research on Progestins and Estrogens (CARPE) Fort Worth, Texas August 1-3, 2003
    James W Simpkins
    J Womens Health (Larchmt) 13:1165-8. 2004
  67. ncbi A clinician's review of the WHI-related literature
    Leon Speroff
    Department of Obstetrics and Gynecology, Oregon Health Sciences University Portland, Oregon 97239, USA
    Int J Fertil Womens Med 49:252-67. 2004
    ....
  68. ncbi The effects of estrogen therapy and estrogen combined with different androgenic progestins on carbohydrate and lipid metabolism in overweight-obese younger postmenopausal women
    Berfu Demir
    Department of Obstetrics and Gynecology, Ministry of Health Ankara Etlik Maternity and Women s Health Teaching Research Hospital, Ankara, Turkey
    Gynecol Endocrinol 24:347-53. 2008
    ..Additionally, the relationship between testosterone and insulin resistance was assessed...
  69. ncbi Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation
    M H Jeng
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792
    Cancer Res 52:6539-46. 1992
    ..Our results may help to explain the conflicting evidence linking OC and breast cancer risk. A rigorous evaluation of the "total" estrogenic potential of OC might produce a better correlation with breast cancer risk...
  70. ncbi Progestin regulation of vascular endothelial growth factor in human breast cancer cells
    S M Hyder
    Department of Integrative Biology, Pharmacology and Physiology, University of Texas Health Sciences Center Houston, 77225, USA
    Cancer Res 58:392-5. 1998
    ....
  71. ncbi Classification and pharmacology of progestins
    Adolf E Schindler
    Institut für Medizinische Forschung und Fortbildung, Universitatsklinikum, Hufelandstr 55, Essen 45147, Germany
    Maturitas 46:S7-S16. 2003
    ..Besides the progestogenic effect, which is in common for all progestins, there is a wide range of biological effects, which are different for the various progestins and have to be taken into account, when medical treatment is considered...
  72. ncbi Classification and pharmacology of progestins
    Adolf E Schindler
    , , Hufelandstr 55, Essen 45147, Germany
    Maturitas 61:171-80. 2008
    ..Besides the progestogenic effect, which is in common for all progestins, there is a wide range of biological effects, which are different for the various progestins and have to be taken into account, when medical treatment is considered...
  73. ncbi Glucocorticoid-recognizing and -effector sites in rat liver plasma membrane. Kinetics of corticosterone uptake by isolated membrane vesicles. III. Specificity and stereospecificity
    C Lackner
    Department of Internal Medicine, University of Graz, Austria
    J Steroid Biochem Mol Biol 64:69-82. 1998
    ..The GC importer seems to be an additional link in the chain of steroid signal transduction and may be functionally involved in the action of natural GC-agonists and GC-antagonists...
  74. ncbi The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Kent Holtorf
    Holtorf Medical Group, Inc, Torrance, CA 90505, USA
    Postgrad Med 121:73-85. 2009
    ..Yet according to the US Food and Drug Administration and The Endocrine Society, there is little or no evidence to support claims that bioidentical hormones are safer or more effective...
  75. ncbi The use of newer progestins for contraception
    Regine Sitruk-Ware
    Population Council and Rockefeller University, New York, NY 10065, USA
    Contraception 82:410-7. 2010
    ..Risks and benefits of the new progestins depend upon the type of molecular structure, the type of estrogen associated in a combination and the route of administration...
  76. ncbi Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate
    C Labrie
    Medical Research Council Group in Molecular Endocrinology, Laval University Medical Center, Quebec, Canada
    Mol Cell Endocrinol 68:169-79. 1990
    ..Consequently, as indicated by this sensitive and androgen-specific in vivo rat model, such compounds are not recommended for the treatment of conditions requiring an optimal blockade of androgens, especially prostate cancer...
  77. ncbi Inhibition of rat ovarian 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD), 17 alpha-hydroxylase and 17,20 lyase by progestins and danazol
    S Arakawa
    Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo, Japan
    Endocrinol Jpn 36:387-94. 1989
    ..3 microM) and danazol (168 microM) inhibited 17 alpha-hydroxylase. All the steroids inhibited 17,20 lyase, and the inhibition by desogestrel (Ki = 0.70 microM), danazol (0.80 microM), and gestrinone (30 microM) was particularly marked...
  78. ncbi Occurrence of androgens and progestogens in wastewater treatment plants and receiving river waters: comparison to estrogens
    Hong Chang
    Laboratory for Earth Surface Processes, College of Urban and Environmental Sciences, Peking University, Beijing, China
    Water Res 45:732-40. 2011
    ..Different profiles of progestogens in the receiving rivers and WWTP effluents were observed, which could be explained by the discharge of a mixture of treated and untreated wastewater into the receiving rivers...
  79. ncbi Reproductive responses in fathead minnow and Japanese medaka following exposure to a synthetic progestin, Norethindrone
    Peter Paulos
    Department of Biology, University of North Texas, Denton, TX 76203, USA
    Aquat Toxicol 99:256-62. 2010
    ..Collectively, these data indicate that further investigation of reproductive responses associated with synthetic progestins is warranted...
  80. ncbi Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice
    M Plante
    Medical Research Council Group in Molecular Endocrinology, Laval University Medical Center, Quebec, Canada
    J Steroid Biochem 31:61-4. 1988
    ....
  81. ncbi Selective effect of chlormadinone acetate on brain allopregnanolone and opioids content
    Nicola Pluchino
    Department of Reproductive Medicine and Child Development, Division of Gynecology and Obstetrics, University of Pisa, 56100 Pisa, Italy
    Contraception 80:53-62. 2009
    ....
  82. ncbi Cell surface-binding sites for progesterone mediate calcium uptake in human sperm
    P F Blackmore
    Department of Pharmacology, Eastern Virginia Medical School, Norfolk 23501
    J Biol Chem 266:18655-9. 1991
    ..It is proposed that a distinct nongenomic cell surface receptor for progesterone exists in human sperm...
  83. ncbi Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase activity
    M Takahashi
    MRC Group in Molecular Endocrinology, CHUL Research Centre, Quebec, Canada
    J Steroid Biochem Mol Biol 37:231-6. 1990
    ..5, 1.7 and 2.5 microM, respectively...
  84. ncbi Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay
    L McRobb
    Heart Research Institute, Sydney, NSW 2050, Australia
    J Steroid Biochem Mol Biol 110:39-47. 2008
    ..By contrast, modern progestins such as progesterone, 17alpha-hydroxyprogesterone and 19-norprogesterone derivatives had minimal androgenic bioactivity and pose low risk...
  85. ncbi Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause
    H Marret
    centre hospitalo universitaire de Tours, Hopital Bretonneau, Service de Gynecologie, Tours 37044 cédex 1, France
    Eur J Obstet Gynecol Reprod Biol 152:133-7. 2010
    ..The prevalence of abnormal uterine bleeding (AUB) is estimated at 11-13% in the general population and increases with age, reaching 24% in those aged 36-40 years...
  86. ncbi Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions
    O Heikinheimo
    Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk 23507, USA
    Contraception 53:55-64. 1996
    ..We conclude that when inhibiting ovulation, RU486 does not act as a progestin agonist, but rather, functions through a hypothalamic mechanism(s), which might be unique to RU486 as a progesterone antagonist...
  87. ncbi Progestagens and mammary gland development: differentiation versus carcinogenesis
    I H Russo
    Department of Pathology, Fox Chase Cancer Center, Philadelphia
    Acta Endocrinol (Copenh) 125:7-12. 1991
    ..DNA labeling index was significantly reduced in terminal ducts and alveolar buds by all hormones at all doses, except PL.(ABSTRACT TRUNCATED AT 250 WORDS)..
  88. ncbi Luteolytic effect of the antiprogestin and antiglucocorticoid agent RU486 in rats
    S Arakawa
    Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo, Japan
    J Steroid Biochem 36:479-83. 1990
    ..These results show that RU486 decreases progesterone synthesis in cultured ovarian cells. A part of the mechanism may involve an inhibition of CSCC...
  89. ncbi Progestins in breast cancer treatment. A review
    S Lundgren
    Department of Oncology, Regional and University Hospital of Trondheim, Norway
    Acta Oncol 31:709-22. 1992
    ..Further studies on the influence of progestin on different receptors and growth factors are warranted. To determine the most effective clinical dose of the two progestins, studies with increasing therapeutic doses are needed...
  90. pmc Mechanisms of cyclin-dependent kinase inactivation by progestins
    E A Musgrove
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Sydney, New South Wales, Australia
    Mol Cell Biol 18:1812-25. 1998
    ..Thus, decreased cyclin expression and consequent increased CDK inhibitor association are likely to mediate the decreases in CDK activity accompanying progestin-mediated growth inhibition...
  91. ncbi Effects of synthetic progestagens on the mRNA expression of androgen receptor, progesterone receptor, oestrogen receptor alpha and beta, insulin-like growth factor-1 (IGF-1) and IGF-1 receptor in heifer tissues
    M W Pfaffl
    Institute of Physiology, Centre of Life and Food Sciences, Technical University of Munich, Germany
    J Vet Med A Physiol Pathol Clin Med 49:57-64. 2002
    ..ERalpha in liver and neck muscle showed a trend of increasing expression...
  92. ncbi Induction of micronuclei and of enzyme-altered foci in the liver of female rats exposed to progesterone and three synthetic progestins
    A Martelli
    Department of Internal Medicine, Division of Clinical Pharmacology and Toxicology, University of Genoa, I 16132, Genoa, Italy
    Mutat Res 419:33-41. 1998
    ..Considered together with previous findings, these results suggest that NE might be biotransformed in the liver into reactive species and thus behave as a weak genotoxic agent...
  93. ncbi Effect of an oral contraceptive with chlormadinone acetate on depressive mood : analysis of data from four observational studies
    Johannes C Huber
    Department of Gynaecology and Obstetrics, Division of Gynaecological Endocrinology and Reproductive Medicine, University of Vienna, Vienna, Austria
    Clin Drug Investig 28:783-91. 2008
    ..The aim of these studies was to describe the clinical effects of CMA in combination with ethinylestradiol on depressive mood symptoms...
  94. ncbi A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone
    Lee P Shulman
    Department of Obstetrics and Gynecology, Division of Reproductive Genetics and Graduate Program in Genetic Counseling, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    J Womens Health (Larchmt) 15:584-90. 2006
    ....
  95. ncbi Contraception
    G R Huggins
    Francis Scott Key Medical Center, Baltimore, Maryland
    Curr Opin Obstet Gynecol 2:291-5. 1990
    ..However, the risk was overstated earlier. Women who have only 1 sexual partner in their lifetime had no significant risk of tubal infertility. "lost" IUDs continue to be a problem...
  96. ncbi Reproductive cycles and contraception of black lemurs (Eulemur macaco macaco) with depot medroxyprogesterone acetate during the breeding season
    Cheryl S Asa
    Saint Louis Zoo, St Louis, Missouri
    Zoo Biol 26:289-98. 2007
    ..Zoo Biol 26:289-298, 2007. (c) 2007 Wiley-Liss, Inc...
  97. ncbi Pharmacological profile of progestins
    Regine Sitruk Ware
    Rockefeller University and Population Council, New York, NY, USA
    Maturitas 61:151-7. 2008
    ..The progestins available for therapy exhibit profound differences according to their structure or metabolites and it is inappropriate to consider the various effects of the old and new molecules as class-effects...
  98. ncbi Pharmacological profile of progestins
    Regine Sitruk-Ware
    Rockefeller University and Population Council, New York, NY, USA
    Maturitas 47:277-83. 2004
    ..The progestins available for therapy exhibit profound differences according to their structure or metabolites and it is inappropriate to consider the various effects of the old and new molecules as class-effects...
  99. ncbi Steroid regulation of prostaglandin dehydrogenase activity and expression in human term placenta and chorio-decidua in relation to labor
    F A Patel
    Department of Physiology, University of Toronto, Ontario, Canada
    J Clin Endocrinol Metab 84:291-9. 1999
    ..We conclude that cortisol inhibits PGDH activity and expression and that progestagens increase PGDH activity in human chorion and placenta...
  100. ncbi [New gestagens--advantages and disadvantages]
    H Kuhl
    Zentrum der Frauenheilkunde und Geburtshilfe, Klinikum der J W Goethe Universität Frankfurt am Main
    Ther Umsch 58:527-33. 2001
    ..According to their different hormonal profiles and activities, the various available progestogens allow the choice of preparations which are best suitable for the individual woman for contraception or hormone replacement therapy...
  101. ncbi Progesterone receptor immunoreactivity differs in the uterus of pseudopregnant and medroxyprogesterone acetate-treated rabbits
    Santiago R Anzaldúa Arce
    Facultad de Medicina Veterinaria y Zootecnia, Departamento de Morfologia, Universidad Nacional Autonoma de Mexico, Ciudad Universitaria, Coyoacan 04510, Mexico, D F, Mexico
    Anim Reprod Sci 120:173-8. 2010
    ..The present study indicated synthetic progestins have different mechanisms of receptor regulation than those of natural hormones and it should be taken into account in reproductive applications...

Research Grants61

  1. Regulation of CD4+ T cell responses by a progesterone receptor
    Grant Hughes; Fiscal Year: 2013
    ....
  2. Identification of novel phytoprogestins from hops and red clover
    Joanna E Burdette; Fiscal Year: 2011
    ..As women search for more potent alternative estrogens to satisfy the need for menopausal symptom alleviation, the chance for hyperplasia in the uterus increases and makes the characterization of novel phytoprogestins crucial. ..
  3. Oral contraceptive use by formulation and breast cancer risk by subtype
    DIANA SM BUIST; Fiscal Year: 2010
    ..This area of research is critical given the high frequency of OC use, heterogeneity of OC formulations, changes in OC formulations over time, and the morbidity and mortality associated with different breast cancer subtypes. ..
  4. Progestin Effects on Uterine Hemostatis &Angiogenesis
    Charles Lockwood; Fiscal Year: 2011
    ..Moreover, a model will be established to test innovative LTPOC formulations that minimize uterine and endometrial vasoconstriction and ROS-generation, thus preventing abnormal bleeding to improve the acceptability of LTPOC therapies. ..
  5. Progesterone Treatment for Cocaine-Dependent Women
    Suzette Evans; Fiscal Year: 2009
    ..e., women who primarily use cocaine by other routes other than smoked). ..
  6. PRENATAL EXPOSURE TO HORMONES IN MAN AND ANIMAL
    JUNE REINISCH; Fiscal Year: 1980
    ....
  7. DEVELOPMENT OF A NOVEL ORAL PROGESTERONE DRUG
    ROBIN FOLDESY; Fiscal Year: 1992
    ..It is further expected that an oral formulation would be more acceptable to patients than rectal, parenteral, or vaginal progesterone formulations...
  8. Progesterone-mediated protection against ovarian cancer
    Shuk Mei Ho; Fiscal Year: 2009
    ..Results from this proposal have the potential to generate new strategies for the prevention and treatment of OCa. ..
  9. Estrogen Receptor Variants,HDL, and Atherosclerosis
    David Herrington; Fiscal Year: 2005
    ....
  10. ESTROGEN, INFLAMMATION AND ATHEROSCLEROSIS
    David Herrington; Fiscal Year: 2001
    ....
  11. Estrogen Receptor Variance and CHD Risk in HERS
    David Herrington; Fiscal Year: 2004
    ..In addition, this information could lead to fundamentally important new knowledge about mechanisms of estrogen action, regulation of HDL cholesterol, and pathogenesis of CHD. ..
  12. Machine Learning to Identify Complex Interactions in Genome-Wide Association Data
    David Herrington; Fiscal Year: 2009
    ..Determining specific genetic and/or environmental factors that influence a person's risk of disease may help doctors reduce risk for disease and reveal new treatments for disease. (End of Abstract) ..
  13. Thrombosis Gene Polymorphisms and Early CHD Risk in HERS
    David Herrington; Fiscal Year: 2004
    ....
  14. Outcomes of Sleep Disorders in Older Men - Pittsburgh
    Jane Cauley; Fiscal Year: 2007
    ..We will also supplement the bank of MrOS specimens to allow for testing of future hypotheses concerning the role of sleep in the development of age-related diseases and conditions. [unreadable] [unreadable]..
  15. PROGESTERONE, TBI AND CNS REPAIR IN MATURE & AGED RATS.
    Donald Stein; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  16. Graylyn Conference on Women's Cognitive Health
    Sally Shumaker; Fiscal Year: 2007
    ..5. Facilitate development of novel approaches to disease prevention, progression and treatment, which can then be tested by new research. [unreadable] [unreadable] [unreadable]..
  17. Mammographic density, genes and estradiol/norethisterone based EPT regimens
    Giske Ursin; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  18. BREAST CANCER PATTERNS OF CARE AND MORBIDITY
    Sandra Norman; Fiscal Year: 2007
    ..Preliminary data from the parent study suggest that only longer follow-up can capture the interplay of time-dependent risks, ongoing treatment, and patient characterisitics that occur over a longer period of time. ..
  19. PDE3 Inhibitors: Selective Blockers of Oocyte Maturation
    Jeffrey Jensen; Fiscal Year: 2007
    ..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
  20. ROLE OF STROMA IN MAMMARY GLAND CELL PROLIFERATION
    SANDRA HASLAM; Fiscal Year: 2007
    ..The long-term goal of this proposal is the delineation of the mechanisms of P-dependent growth regulation in the adult normal mammary gland that may lead to novel strategies for the prevention and treatment of breast cancer. ..
  21. Stress, Sleep and Emerging CVD Risk Factors
    Karen Matthews; Fiscal Year: 2007
    ..The study will provide novel data testing the relationships of daytime stressful events, SDB, and other nocturnal physiological measures with the emerging risk factors and subclinical CVD measured in HeartSCORE. [unreadable] [unreadable]..
  22. Effects of Perinatal Depression on PTD and LBW
    Kimberly Yonkers; Fiscal Year: 2008
    ..Further, if we determine antidepressants increase the risk of adverse perinatal outcomes, treatment with psychotherapy rather than antidepressants should be considered when recommending therapeutic options. [unreadable] [unreadable]..
  23. Psychosocial Res. to Improve Drug Treatment in Pregnancy
    Kimberly Yonkers; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  24. Phase III Study of Donepezil in the Irradiated Brain
    Stephen R Rapp; Fiscal Year: 2010
    ..If successful the study will offer physicians a treatment for radiation-induced cognitive impairment which also may improve mood and quality of life. ..
  25. Prophylactic Ibuprofen: Effect on IUD Continuation Rates
    David Hubacher; Fiscal Year: 2003
    ..In the US, ibuprofen may help spur renewed interest in the most cost effective and efficacious reversible contraceptive method available. ..
  26. A MECHANISTIC STUDY OF SKELETAL ACTIONS OF 1-34hPTH
    Robert Lindsay; Fiscal Year: 2009
    ..abstract_text> ..
  27. Soy and Estrogen Interactions in the Breast
    J Cline; Fiscal Year: 2009
    ..The proposed work will provide a unique view of an otherwise inaccessible period of breast development in a primate model with high genetic and physiologic similarity to human beings. ..
  28. Determination of RDA for Vitamin D in Caucasian and African American Women
    John Gallagher; Fiscal Year: 2009
    ..The results from this study will also help in designing future larger clinical trials of the effect of vitamin D on falls and fractures. ..
  29. Estrogen and progestin crosstalk via binding of PR at estrogen response elements
    STEVEN NORDEEN; Fiscal Year: 2008
    ..abstract_text> ..
  30. Oral Androgen Administration and Function in Man
    JOHN AMORY; Fiscal Year: 2008
    ..Matsumoto M.D., Director, Clinical Research Unit VA-Puget Sound and Professor of Medicine, University of Washington School of Medicine will co-mentor this award. [unreadable] [unreadable]..
  31. Atherosclerosis Stage, Estrogen Receptors, and Vascular Responses to Estrogen
    THOMAS COSTIN REGISTER; Fiscal Year: 2010
    ....
  32. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2006
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
  33. Control of menstrual bleeding disturbances in women
    Ian Fraser; Fiscal Year: 2006
    ..This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice. ..
  34. CHLORHEXIDINE IRRIGATION TO PREVENT INFECTION
    Dwight Rouse; Fiscal Year: 2001
    ....
  35. VASCULAR INTERACTION WITH AGE IN MYOCARDIAL INFARCTION
    Steven Schulman; Fiscal Year: 2004
    ..We anticipate that the study findings will suggest the use of new evaluation and therapeutic strategies, which will significantly decrease the age associated mortality and morbidity in post-infarction patients. ..
  36. Pregnancy Hormonal Profile/Biomarker Breast Cancer Risk
    Alan Arslan; Fiscal Year: 2004
    ..Moreover, specific hormone(s) or its analogues responsible for protective effect of pregnancy against breast cancer could be used for development of novel strategies for primary chemoprevention of breast cancer. ..
  37. MIDCAREER AWARD IN PATIENT ORIENTED OBSTETRIC RESEARCH
    Dwight Rouse; Fiscal Year: 2004
    ..Finally, the effectiveness of an intervention (how it would perform under conditions of actual clinical practice) is an attribute that, in many situations, is as important as its efficacy (how it performs under ideal conditions). ..
  38. Biomarkers of Ovarian Cancer Risk: A Prospective Study
    Alan Arslan; Fiscal Year: 2004
    ....
  39. 9th annual Graylyn Conference: Women's Cognitive Health
    Sally Shumaker; Fiscal Year: 2003
    ..5. Provide opportunities for students and junior faculty to participate in the process. 6. Facilitate development of novel approaches to disease prevention, progression and treatment, which can be tested. ..
  40. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2003
    ..abstract_text> ..
  41. Treating PMS/PMDD--Research versus Clinical Reality
    Kimberly Yonkers; Fiscal Year: 2003
    ....
  42. DETECTION AND TREATMENT OF POSTPARTUM DEPRESSION
    Kimberly Yonkers; Fiscal Year: 2003
    ..abstract_text> ..
  43. Progestin Regulation of VEGF in Breast Cancer Cells
    SALMAN HYDER; Fiscal Year: 2005
    ..abstract_text> ..
  44. PROGESTERONE AFTER TRAUMATIC BRAIN INJURY
    Donald Stein; Fiscal Year: 2005
    ..Furthermore, the detailed assessment of progesterone's mechanisms of action will provide a foundation for the intelligent design of artificial therapeutic pharmaceuticals. ..
  45. Chaperones, chromatin, and transcriptional control by PR
    STEVEN NORDEEN; Fiscal Year: 2006
    ..Together, the studies proposed will provide fundamental knowledge that will advance our understanding of steroid receptor action in human health and disease. ..
  46. 10th Annual Graylyn Conference on Women's Cognitive Health
    Sally Shumaker; Fiscal Year: 2005
    ..4. Provide opportunities for students and junior faculty to participate in the process. 5. Facilitate development of novel approaches to disease prevention, progression and treatment, which can then be tested by new research. ..
  47. ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2
    Mark Hlatky; Fiscal Year: 2006
    ..The investigators further expect that this collaborative effort will translate into a new practical clinical paradigm that will be used for treatment of Type II diabetic patients. ..
  48. Hormones and Biomarkers Predicting Stroke in Women
    Sylvia Wassertheil Smoller; Fiscal Year: 2005
    ..abstract_text> ..
  49. STUDY OF OSTEOPOROTIC FRACTURES
    Jane Cauley; Fiscal Year: 2005
    ....
  50. Depo-provera & BMD: Continuing Observations
    M Clark; Fiscal Year: 2005
    ..The longitudinal design will be continued, maintaining all methods and protocols employed in the parent study. ..
  51. Serum Vitamin D, Genetic Polymorphisms & Ovarian Cancer
    Alan Arslan; Fiscal Year: 2005
    ..abstract_text> ..
  52. MOLECULAR MECHANISMS OF GLUCOCORTICOID HORMONE ACTION
    STEVEN NORDEEN; Fiscal Year: 2004
    ..Together these studies will make significant contributions to our understanding of hormone action. ..
  53. Ventricular Size and Valve Calcification Measures by CT
    Matthew J Budoff; Fiscal Year: 2010
    ..abstract_text> ..
  54. The effects of progesterone and its metabolites on TBI
    Donald Stein; Fiscal Year: 2004
    ..abstract_text> ..
  55. Pittsburgh Mind-Body Center-II
    Karen Matthews; Fiscal Year: 2008
    ..Support-in-kind from the host institutions will enable us to leverage the funds provided by the RFA to expand Center activities that would not otherwise be possible. ..
  56. Estradiol, Cytokines & Bone Turnover--Effects on Fracture
    Jane Cauley; Fiscal Year: 2007
    ..Improved understanding of the biological mechanisms for these associations could lead to the development and testing of preventive intervention. ..
  57. Recovery of functional p53 as a therapeutic approach for breast cancer
    SALMAN HYDER; Fiscal Year: 2008
    ..Furthermore, we contend that the research will provide critical data relevant to minimizing breast cancer risk and metastasis in post-menopausal women and other women exposed to exogenous progestins. ..
  58. Effects of Dietary Soy on Biomarkers in Prostate Cancer
    J Cline; Fiscal Year: 2004
    ..abstract_text> ..
  59. 6th International Symposium on Osteoporosis
    Robert Lindsay; Fiscal Year: 2005
    ..abstract_text> ..
  60. ANXIETY, DISINHIBITION, AND RISK FOR DRUG ABUSE
    Kimberly Yonkers; Fiscal Year: 2003
    ..phenotypic indices of vulnerability using combinations of clinical and psychophysiological measures. ..